Literature DB >> 2725797

Clinical relevance of lysozyme in the faeces.

M H Hemrika, G M Costongs, L G Engels, L P Bos, P C Janson, J A Flendrig.   

Abstract

To elucidate the value of faecal lysozyme determination in the differential diagnosis of patients with atypical abdominal complaints, stool samples of healthy controls, patients with irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) were analysed. Faecal lysozyme concentration in healthy controls ranged from 0 to 6 mg/l with a mean of 3 mg/l. Patients with IBS had similar faecal lysozyme levels. In contrast, faecal lysozyme concentrations in patients with IBD were increased (range 6 to 104 mg/l). The difference between patients with IBS and IBD was highly significant (P less than 0.001). The determination of faecal lysozyme concentration may provide a useful test in the work-up of patients with abdominal complaints. In addition, the faeces lysozyme concentration appeared to be an objective parameter of the inflammatory activity of IBD in 11 patients investigated.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2725797

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  2 in total

1.  Lysozyme promotes the release of Toll-like receptor-2 stimulants from gram-positive but not gram-negative intestinal bacteria.

Authors:  Clett Erridge
Journal:  Gut Microbes       Date:  2010 Nov-Dec

2.  Fecal lysozyme in assessment of disease activity in inflammatory bowel disease.

Authors:  A van der Sluys Veer; J Brouwer; I Biemond; G E Bohbouth; H W Verspaget; C B Lamers
Journal:  Dig Dis Sci       Date:  1998-03       Impact factor: 3.199

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.